<DOC>
	<DOCNO>NCT01380600</DOCNO>
	<brief_summary>The purpose pilot safety study evaluate safety tolerability JX-594 ( Pexa-Vec ) administer intravenously every 2 week colorectal carcinoma patient refractory intolerant oxaliplatin , irinotecan , Erbitux treatment .</brief_summary>
	<brief_title>Safety Study Recombinant Vaccinia Virus Administered Intravenously Patients With Metastatic , Refractory Colorectal Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Vaccinia</mesh_term>
	<criteria>Histologicallyconfirmed , advanced/metastatic colorectal carcinoma Failed oxaliplatin irinotecan base regimen advanced/metastatic disease ( tumor advance either immediately within 3 month end treatment ) Resistance Erbitux : patient Ras mutation , Erbitux fail ( tumor advance either immediately within 3 month end treatment , response Erbitux therapy due lack expression EGFR ( epidermal growth factor ) ) Karnofsky Performance Score ( KPS ) ≥ 70 Age ≥18 year Laboratory Safety : WBC ≥ 3,500 cells/mm3 ≤ 50,000 cells/mm3 , ANC ≥ 1,500 cells/mm3 , Hemoglobin ≥ 10 g/dL ( transfusion allow ) , Platelet count ≥ 100,000 plts/mm3 , Total bilirubin ≤ 1.5 X ULN , INR ≤ 1.5 , AST , ALT ≤ 2.5x ULN ( case liver metastasis : AST , ALT ≤5.0 x ULN ) Serum chemistry within normal limit ( WNL ) Grade 1 ( exclude alkaline phosphatase ) If patient diabetic , fast glucose must do patient must &gt; 160 mg/dL . Patients , sexually active , willing able refrain sexual activity 3 week follow JX594 administration . Patients willing able use permit contraceptive 3 month final administration JX594 . Significant immunodeficiency due underlie illness ( e.g . HIV/AIDS ) and/or medication ( e.g . systemic corticosteroid ) Known myeloproliferative disorder require systemic therapy History exfoliative skin condition ( e.g . eczema ectopic dermatitis ) require systemic therapy History acquire opportunistic infection . Tumor ( ) invade major vascular structure ( e.g . carotid artery ) Tumor ( ) location would potentially result significant clinical adverse effect posttreatment tumor swell occur Clinically uncontrolled and/or rapidly accumulate ascites , pericardial and/or pleural effusion History severe unstable cardiac disease Current , know CNS malignancy ( history completely resect irradiated brain metastasis WBRT stereotactic radiosurgery allow ) Administered anticancer therapy within 4 week prior first treatment ( 6 week case mitomycin C nitrosoureas ) Use antiviral , antiplatelet , anticoagulation medication [ Patients discontinue medication within 7 day prior first treatment may eligible study . ] Low dose aspirin ( approximately 81 mg ) allow . Pulse oximetry O2 saturation &lt; 90 % Pulse oximetry O2 saturation &lt; 90 % rest Experienced severe systemic reaction sideeffect result previous smallpox vaccination Pregnant nursing Household contact exclusion : Women pregnant nursing infant Children &lt; 5 year old People skin disease ( e.g . eczema , atopic dermatitis , related disease Immunocompromised host ( severe deficiency cellmediated immunity , include AIDS , organ transplant recipient , hematologic malignancy )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>Vaccinia</keyword>
	<keyword>Vaccinia Virus</keyword>
	<keyword>JX-594</keyword>
	<keyword>Jennerex</keyword>
	<keyword>Colorectal Carcinoma</keyword>
	<keyword>Colorectal cancer</keyword>
	<keyword>Colon Cancer</keyword>
	<keyword>Rectal Cancer</keyword>
	<keyword>Pexa-Vec</keyword>
</DOC>